LBA70 - Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a randomized, open-label, phase II trial

J.A Chesney,I Puzanov,F Collichio,P Singh,M Milhem,J Glaspy,O Hamid,M.I Ross,P Friedlander,C Garbe,T Logan,A Hauschild,C Lebbe,M Yi,A Sharma,J.M Mehnert

doi:10.1093/annonc/mdz394.067

LBA70 - Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a randomized, open-label, phase II trial

J.A Chesney, I Puzanov + Show 14 more

Open Access

https://doi.org/10.1093/annonc/mdz394.067

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2019
Citations: 9	License type: publisher-specific-oa

Affiliation: University of Louisville, University North, University of Iowa Hospitals and Clinics, University of California, Los Angeles, The University of Texas MD Anderson Cancer Center, Indiana University Indianapolis

#Research Grant #Funding Institution + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

LBA70 - Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a randomized, open-label, phase II trial

Full Text